Zeidan AM - Search Results

1

TIM-3 pathway dysregulation and targeting in cancer.

Zeidan AM, Komrokji RS, Brunner AM. Zeidan AM, et al. Expert Rev Anticancer Ther. 2021 May;21(5):523-534. doi: 10.1080/14737140.2021.1865814. Epub 2021 Jan 19. Expert Rev Anticancer Ther. 2021. PMID: 33334180 Review.

2

Prognostication in myelodysplastic syndromes: beyond the International Prognostic Scoring System (IPSS).

Zeidan AM, Smith BD, Komrokji RS, Gore SD. Zeidan AM, et al. Am J Med. 2013 Apr;126(4):e25. doi: 10.1016/j.amjmed.2012.08.013. Am J Med. 2013. PMID: 23507216 Free PMC article. No abstract available.

3

Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?

Zeidan AM, Gore SD, Komrokji RS. Zeidan AM, et al. Expert Rev Hematol. 2013 Jun;6(3):251-4. doi: 10.1586/ehm.13.30. Expert Rev Hematol. 2013. PMID: 23782079

4

There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.

Zeidan AM, Komrokji RS. Zeidan AM, et al. Curr Hematol Malig Rep. 2013 Dec;8(4):351-60. doi: 10.1007/s11899-013-0172-3. Curr Hematol Malig Rep. 2013. PMID: 23979829 Free PMC article. Review.

5

Beyond hypomethylating agents failure in patients with myelodysplastic syndromes.

Zeidan AM, Kharfan-Dabaja MA, Komrokji RS. Zeidan AM, et al. Curr Opin Hematol. 2014 Mar;21(2):123-30. doi: 10.1097/MOH.0000000000000016. Curr Opin Hematol. 2014. PMID: 24335709 Free PMC article. Review.

6

Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes.

Abou Zahr A, Saad Aldin E, Komrokji RS, Zeidan AM. Abou Zahr A, et al. Among authors: zeidan am. J Blood Med. 2014 Dec 22;6:1-16. doi: 10.2147/JBM.S50482. eCollection 2015. J Blood Med. 2014. PMID: 25565910 Free PMC article. Review.

7

Current state of prognostication and risk stratification in myelodysplastic syndromes.

Zeidan AM, Gore SD, Padron E, Komrokji RS. Zeidan AM, et al. Curr Opin Hematol. 2015 Mar;22(2):146-54. doi: 10.1097/MOH.0000000000000110. Curr Opin Hematol. 2015. PMID: 25575032 Review.

8

Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?

Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, DeZern A, Maciejewski JP, List AF, Komrokji RS; MDS Clinical Research Consortium (Funded by Edward P. Evans Foundation). Zeidan AM, et al. Am J Hematol. 2015 Nov;90(11):1036-40. doi: 10.1002/ajh.24173. Am J Hematol. 2015. PMID: 26284571 Free article.

9

Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.

Zeidan AM, Al Ali NH, Padron E, Lancet J, List A, Komrokji RS. Zeidan AM, et al. Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):705-10. doi: 10.1016/j.clml.2015.08.083. Epub 2015 Sep 2. Clin Lymphoma Myeloma Leuk. 2015. PMID: 26440749

10

Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.

Zeidan AM, Sekeres MA, Garcia-Manero G, Steensma DP, Zell K, Barnard J, Ali NA, Zimmerman C, Roboz G, DeZern A, Nazha A, Jabbour E, Kantarjian H, Gore SD, Maciejewski JP, List A, Komrokji R; MDS Clinical Research Consortium. Zeidan AM, et al. Leukemia. 2016 Mar;30(3):649-57. doi: 10.1038/leu.2015.283. Epub 2015 Oct 14. Leukemia. 2016. PMID: 26464171 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

334 results

Search Page